KPC Medical College and Hospital, Kolkata, India.
Int J Gynaecol Obstet. 2010 Sep;110(3):213-6. doi: 10.1016/j.ijgo.2010.04.023. Epub 2010 Jun 8.
To study the effects of 6 months of treatment with transdermal estradiol gel versus oral tibolone on health-related quality of life (HRQOL) after surgical menopause.
In a randomized single-blind trial, Indian women received either oral tibolone tablets (2.5 mg) or transdermal estradiol gel (0.06%) daily. Each woman scored herself on the Menopause Rating Scale (MRS) II at the beginning of the study and after 6 months. Independent t tests were used to determine the significance of changes in HRQOL.
In total, 31 (81.6%) women who received estradiol gel and 38 (100.0%) women who received tibolone completed treatment. Intent-to-treat analysis showed that, after 6 months of treatment, the total MRS score was significantly reduced in the tibolone group compared with the transdermal estradiol gel group (-9.5+/-5.1 versus -4.9+/-5.7; 95% confidence interval, 2.0-7.0; P<0.01). Significant improvements were also noted in the tibolone group in terms of somatovegetative (P=0.04) and psychologic (P<0.01) domains.
Oral tibolone treatment was more effective than transdermal estradiol gel at improving HRQOL in Indian women with surgical menopause.
研究 6 个月经皮雌二醇凝胶与口服替勃龙治疗对手术绝经后健康相关生活质量（HRQOL）的影响。
在一项随机单盲试验中，印度女性每天接受口服替勃龙片（2.5 毫克）或经皮雌二醇凝胶（0.06%）治疗。每位女性在研究开始时和 6 个月后均使用绝经评定量表（MRS）Ⅱ对自己进行评分。采用独立 t 检验确定 HRQOL 变化的显著性。
共有 31 名（81.6%）接受雌二醇凝胶治疗的女性和 38 名（100.0%）接受替勃龙治疗的女性完成了治疗。意向治疗分析显示，替勃龙组治疗 6 个月后，MRS 总分较经皮雌二醇凝胶组显著降低（-9.5±5.1 比-4.9±5.7；95%置信区间，2.0-7.0；P<0.01）。替勃龙组在躯体植物神经（P=0.04）和心理（P<0.01）方面也有显著改善。
与经皮雌二醇凝胶相比，口服替勃龙治疗更能有效改善印度手术绝经后女性的 HRQOL。
